The RAF Inhibitor Paradox Revisited

Slides:



Advertisements
Similar presentations
Origins of Metastatic Traits Sakari Vanharanta, Joan Massagué Cancer Cell Volume 24, Issue 4, Pages (October 2013) DOI: /j.ccr
Advertisements

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell Volume.
Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity Cai-Hong.
Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm Thierry Soussi, Klas G. Wiman Cancer Cell Volume 12, Issue 4, Pages (October.
Inflammation and Cancer: IL-6 and STAT3 Complete the Link
Kicking Genomic Profiling to the Curb: How Re-wiring the Phosphoproteome Can Explain Treatment Resistance in Glioma  Fred C. Lam, Michael B. Yaffe  Cancer.
The Kinase-Independent, Second Life of CDK6 in Transcription
Charles Swanton, Julian Downward  Cancer Cell 
Inhibitor of MAP kinase activation blocks colon cancer growth
MAPK pathway inhibitors.
BRAF inhibitor: targeted therapy in hairy cell leukemia
Carlos L. Arteaga, Jeffrey A. Engelman  Cancer Cell 
Taking the Stress out of Melanoma
mTOR Signaling in Melanoma: Oncogene-Induced Pseudo-Senescence?
c-Kit as a Novel Potential Therapeutic Target in Colorectal Cancer
Figure 4 Possible combination therapies CDK4/6 inhibitors
Volume 14, Issue 2, Pages (August 2008)
Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma  Darshil J. Shah, MD, MPH, Roxana S. Dronca,
The Akt-mTOR tango and its relevance to cancer
Killing Tumors by Keeping Ras and PI3′ Kinase Apart
G. Aaron Hobbs, Alfred Wittinghofer, Channing J. Der  Cancer Cell 
Volume 28, Issue 3, Pages (September 2015)
Volume 26, Issue 1, Pages 1-2 (July 2014)
Suppressing NFAT Increases VEGF Signaling in Hemangiomas
The Wind God Promotes Lung Cancer
Targeted Therapies in Melanoma: Translational Research at Its Finest
A Radical Role for p38 MAPK in Tumor Initiation
Volume 29, Issue 3, Pages (March 2016)
Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer  Vassiliki Papadimitrakopoulou,
On the TRAIL to Overcome BRAF-Inhibitor Resistance
A genome-based strategy uncovers frequent BRAF mutations in melanoma
Coordinate Transcriptional Regulation by ERG and Androgen Receptor in Fusion- Positive Prostate Cancers  Yu Chen, Charles L. Sawyers  Cancer Cell  Volume.
Inflammation, Epithelial to Mesenchymal Transition, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance  Kostyantyn Krysan, PhD,
A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin 
The p27Kip1 tumor suppressor gene: Still a suspect or proven guilty?
Raf-1 and Squamous Cell Carcinoma: Rok-ing the Boat
Taru Muranen, Funda Meric-Bernstam, Gordon B. Mills  Cancer Cell 
Keiran S.M. Smalley  Journal of Investigative Dermatology 
PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles
A New “Brew” of MALT1 Inhibitors
A Mediator Lost in the War on Cancer
Volume 23, Issue 5, Pages (May 2013)
Volume 20, Issue 6, Pages (December 2011)
The RAS/MAPK Axis Gets Stressed Out
PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles
RAS and PD-L1: A Masters’ Liaison in Cancer Immune Evasion
LKB1 and Src: Antagonistic Regulators of Tumor Growth and Metastasis
Hard Times for Oncogenic BRAF-Expressing Melanoma Cells
Model of the BET and MEK inhibitor combination therapy to treat melanoma with NRAS mutation and immune therapy resistance Model of the BET and MEK inhibitor.
HATs On for Drug Resistance
Scott A. Foster, Christiaan Klijn, Shiva Malek  Trends in Cancer 
William G. Nelson, Michael C. Haffner, Srinivasan Yegnasubramanian 
Volume 14, Issue 4, Pages (October 2008)
Volume 8, Issue 4, Pages (August 2014)
Smoothing Out Drug Resistance
Volume 22, Issue 5, Pages (November 2012)
Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer  Charles M.
The new kid on the block(ade) of the IGF-1 receptor
Under Pressure: Stromal Fibroblasts Change Their Ways
Mutant BRAF Melanomas—Dependence and Resistance
To Infinium, and Beyond! Cancer Cell
Guilty as charged Cancer Cell
Co-opted integrin signaling in ErbB2-induced mammary tumor progression
Discovery of a Secreted Tumor Suppressor Provides a Promising Therapeutic Strategy for Follicular Lymphoma  Marc R. Mansour, A. Thomas Look  Cancer Cell 
c-Raf in KRas Mutant Cancers: A Moving Target
Simplified BRAF signaling network.
Ibrutinib Treatment of CLL: The Cancer Fights Back
Mind the IQGAP Cancer Cell
Volume 12, Issue 6, Pages (December 2007)
Tackling Resistance to PI3K Inhibition by Targeting the Epigenome
Presentation transcript:

The RAF Inhibitor Paradox Revisited Adrienne D. Cox, Channing J. Der  Cancer Cell  Volume 21, Issue 2, Pages 147-149 (February 2012) DOI: 10.1016/j.ccr.2012.01.017 Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 1 Consequences of RAF Inhibitor Therapy Cellular responses to vemurafenib treatment in BRAF mutant melanoma or RAS mutant skin epithelial cells. In both settings, concurrent treatment with a MEK inhibitor may decrease the onset of these mechanisms of tumor resistance or tumor progression. (A) Resistance mechanisms for BRAF mutant melanomas. Inactivation of BRAF (V600E) mutant by RAF inhibitor initially leads to inhibition of MEK-ERK signaling. However, tumor cells can develop resistance by multiple mechanisms, including upregulated expression of receptor tyrosine kinases (RTK) or mutational activation of NRAS leading to CRAF-dependent activation of MEK or by overexpression of the COT/TPL2 serine/threonine protein kinase, a direct activator of MEK1/2. (B) Mutationally activated RAS forms a complex with a BRAF/CRAF heterodimer. RAF inhibitor binds preferentially to BRAF and inactivates it but also causes transactivation of the associated CRAF, enhancing MEK-ERK activation and cellular proliferation. Cancer Cell 2012 21, 147-149DOI: (10.1016/j.ccr.2012.01.017) Copyright © 2012 Elsevier Inc. Terms and Conditions